Merck announced a collaboration with IPS-Integrated Project Services, LLC and G-CON Manufacturing Inc. to provide the most advanced 2,000L monoclonal antibody (MAb) facility and single-use process technology platform. The deal will extend Merck’s BioReliance® End-to-End offering by integrating Merck’s single-use process equipment, end-to-end process development capabilities and cGMP manufacturing experience into the iCON™ facility design platform, for a true turnkey modular facility solution. The integrated end-to-end offering will deliver an innovative platform for fast and flexible deployment of 2,000L MAb production facilities. The hallmarks of the combined solution will include pre-fabricated cleanroom units, a structural platform based on cost-effective pre-engineered building delivery, bioprocess and single-use equipment expertise, as well as turnkey facilities capable of fast-track deployment. This collaboration extends Merck’s BioReliance® End-to-End offering — a comprehensive suite of products and services that help biopharmaceutical companies accelerate the progression of molecules into the clinic and toward commercialization. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialization.